Who Paid My Doc
James Daniels
Otology & Neurotology Dallas, TX Medical Doctor
NPI 1427064088 CMS profile 110024
2001 Inwood Road Suite Wc5, Dallas, TX 75390
General payments
$6,957
Research payments
$21,488
Ownership & investment interest
$0
Research they led as principal investigator
$144,256
Through program year 2025, James Daniels of Dallas, TX is reported in the CMS Open Payments database as having received $6,957 across 36 general payments and $21,488 in research payments paid to them. Separately, studies naming them as principal investigator received $144,256 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $557 | 3 | |
| 2025 | Research | $7,313 | 4 | |
| 2024 | General | $1,540 | 16 | |
| 2024 | Research | $8,550 | 3 | |
| 2023 | General | $3,227 | 3 | |
| 2023 | Research | $675 | 1 | |
| 2022 | General | $668 | 5 | |
| 2022 | Research | $2,250 | 2 | |
| 2021 | Research | $2,700 | 2 | |
| 2019 | General | $965 | 9 |
Beside peers
- James Daniels
- Otology & Neurotology median
- Middle half of Otology & Neurotology
- National median
In program year 2025, general payments to James Daniels were reported at $557. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.
Show as a table
| Year | James Daniels | Otology & Neurotology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $965 | $349 | $117–$1,358 | $163 |
| 2020 | $0 | $118 | $58–$325 | $114 |
| 2021 | $0 | $186 | $81–$600 | $132 |
| 2022 | $668 | $290 | $129–$938 | $149 |
| 2023 | $3,227 | $335 | $119–$978 | $160 |
| 2024 | $1,540 | $399 | $138–$1,384 | $164 |
| 2025 | $557 | $411 | $148–$1,608 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
724
Drug cost
$335,838
Branded share of claims
41.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 199 | $251,935 | |
| Xarelto Rivaroxaban | Brand | 52 | $57,174 | |
| Dofetilide | Generic | 61 | $17,609 | |
| Propafenone Hcl Er Propafenone Hcl | Brand | 15 | $2,710 | |
| Metoprolol Succinate | Generic | 115 | $1,869 | |
| Flecainide Acetate | Generic | 20 | $908 | |
| Amiodarone Hcl | Generic | 60 | $796 | |
| Propafenone Hcl | Generic | 20 | $791 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 13 | $500 | |
| Metoprolol Tartrate | Generic | 27 | $322 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 72 billing codesPaid by Medicare
$159,037
Medicare patients
1,075
Services billed
2,373
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 65% | |
| Arthritis | 57% | |
| Heart failure | 52% | |
| Ischemic heart disease | 52% | |
| Chronic kidney disease | 42% | |
| Diabetes | 38% | |
| Depression | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Otology & Neurotology in Texas
Related records
Otology & Neurotology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Otology & Neurotology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.